Humana Inc. (NYSE:HUM) closed at $420.38 on October 13. The stock has returned 112% over the last six months, compared to a 21.5% return by the Insider Monkey Billionaire Index and 14.0% for the State Street SPDR S&P 500 ETF Trust.
Humana sells private health plans to people on Medicare, and the government grades those plans out of five stars. The grade decides whether Washington pays the insurer a bonus on top of its usual rate. Humana had been failing that test badly, and it has just stopped failing.
READ ALSO: 10 Most Profitable Undervalued Stocks to Invest In
Ninety-Five Percent, Up From Twenty:
The scorecard published this month covers 2027. Humana now expects 95% of its Medicare members to sit in plans rated four stars or better, against 20% a year earlier, and comfortably ahead of what analysts had modelled.
That matters more here than it would almost anywhere else, because the margins are desperately thin. Humana keeps 3.46% of its revenue as operating profit, so on revenue this size a small change in what the government pays is the difference between a weak year and a strong one. Revenue grew 26.20% in the most recent quarter. A swing of this kind is what puts a name on the turnaround candidates we picked for 2026.
The Money Arrives in 2028:
The ratings published this month decide what Washington pays in 2028. Nothing in next year’s accounts changes because of them, and the gap between the announcement and the cash is two full years. The size of the eventual benefit is an analyst’s estimate rather than the company’s. The figure most often quoted is around $4.8 billion, and it came from a broker rather than from Humana.
There is also a catch most of the coverage skipped. Bonus money in this industry is routinely spent on better benefits to hold on to members, rather than kept as profit. That is the difference between the shares being worth more and the shares merely costing more, and it is why value buyers tend to look at the cheapest large companies listed in New York instead. The one we rated first has returned 13% since.
The Valuation Case:
The stock trades at 24.33 times next year’s expected earnings, on analyst consensus estimates, and the shares have already more than doubled in six months. The trailing multiple is 35.42.
The verdict is that Humana is expensive on what it earns today and reasonable only if the 2028 bonus arrives and is kept. The price assumes a good deal of that already, so what a buyer is paying for now is two years of execution rather than a mispricing.
DON’T MISS: 10 Best Stocks to Buy Now for Good Returns
Conclusion:
A government scorecard did the work here, and it did a great deal of it. Almost all of Humana’s Medicare members are moving into bonus-paying plans, from a small minority a year ago, and on margins this thin that matters more than anything management could do by itself. However, the payments land two years out. The headline benefit figure is a broker’s estimate, and money like this is often spent on members rather than kept. The share price has already travelled most of the distance. The figure to follow is the operating margin, because that is where a bonus either lands or gets spent.
Market Sentiment:
Humana Inc. was held by 74 hedge funds with a combined stake value of about $7.70 billion at the end of Q2 2026 in the Insider Monkey database. This is up from 61 hedge fund holders with a cumulative investment value of around $2.94 billion in the previous quarter.
While we acknowledge the risk and potential of HUM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HUM and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Stocks to Buy Now for Good Returns and 10 Most Profitable Undervalued Stocks to Invest In
This article is originally published at Insider Monkey.
Hedge Fund Resource Center